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ABSTRACT 
Objective: Drug utilization studies provide useful insights into the current prescribing practices. In view of this, the present study was designed to 
establish the drug utilization pattern in hospitalized chronic obstructive pulmonary disease (COPD) patients. 
Methods: In this retrospective study, all patient data relevant to the study were obtained by examination of patient’s medical records and hospital 
information system.  
Results: A total of 237 patients with acute exacerbation were evaluated. The population predominantly consisted of males (92.4%) and most of the 
patients were in the age group of 61 to 70 y (39.7%). Cough, sputum production and dyspnea were observed in 88.2%, 80.6% and 37.6% patients, 
respectively. Hypertension (49.4%) was the most common co-morbidity. Candida albicans (16%) and Pseudomonas aeruginosa (4.6%) were the 
most common microorganisms isolated from sputum samples.  
Majority of the patients were on multidrug therapy during both hospital stay (98.7%) and at the time of discharge (99.6%). During hospital stay, the 
most commonly prescribed drugs were ipratropium (91.6%) and levosalbutamol (88.2%); antibiotics and systemic corticosteroids were received 
by 96.2% and 83.1% patients, respectively. At discharge, antibiotics, inhaled corticosteroids, methyl xanthines, long acting beta-2 agonist and 
tiotropium were received by 94.1%, 93.7%, 92.4%, 86.1% and 56.5% patients, respectively.  
Conclusion: The prescribing trend observed at our hospital appears to be in concordance with the current guidelines for the management of COPD 
patients. 
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Chronic obstructive pulmonary disease (COPD) is a significant public 
health problem worldwide including India, with cigarette smoking 
being the primary risk factor. It is projected that COPD will be the 
fourth leading cause of death in 2030, accounting for 7.8 % of total 
deaths. There are wide variations in the prevalence of COPD across 
countries, with it being higher in patients with a smoking history, 
those over 40 y of age, and in men than in women [1-4]. 
Exacerbation in COPD is defined as an acute event characterized by a 
worsening of the patient’s respiratory symptoms that is beyond 
normal day-to-day variations and leads to a change in medication. 
Several factors exacerbate COPD and the common factors are 
bacterial or viral respiratory tract infections. The treatment of 
exacerbations in COPD is with bronchodilators, corticosteroids and 
antibiotics [1, 5-7].  
According to World Health Organization, drug utilization is defined 
as the marketing, distribution, prescription and use of drugs in a 
society with special emphasis on the resulting medical, social and 
economic consequences [8]. Drug utilization studies provide useful 
insights into the current prescribing practices and can thus help in 
reforming and updating practices in clinical medicine and 
pharmacotherapy. In view of this, the present study was designed to 
establish the drug utilization pattern in hospitalized COPD patients. 
This retrospective study was conducted in the Pulmonary Medicine 
Department of Amrita Institute of Medical Sciences and Research 
Centre. The research protocol was approved by the Institutional 
Ethics Committee. The study population included adult COPD 
inpatients of either sex evaluated during the study period (January 
2012 to June 2013). Pregnant and lactating females; and patients 
with any malignancy or those who were immunocompromised were 
excluded. Information on patient’s age, sex, smoking history, COPD 
signs and symptoms, co-morbid conditions, microbiology details and 
medications prescribed (during hospital stay and at discharge) were 
extracted from medical records and hospital information system in 
computer and then transcribed into standard data collection forms. 
A total of 237 patients admitted due to exacerbations of COPD were 
evaluated. The study population predominantly consisted of males 
(92.4%). Most of the patients were above 40 y (99.2%) with 
majority being in the age group of 61 to 70 y (table 1). The mean age 
of the patients was 67.8 y (age range: 33-89 y). The sex and age 
distribution of the patients in the present study further provided 
support to previous reports that have accounted male sex and 
patients over 40 y of age to be more affected by the disease [1, 9]. 
Among the 237 patients, 148 patients were ex-smokers while 29 
patients were current smokers. Three patients had no smoking 
history. Data on smoking history were not available for 57 patients.  
Cough was the most common symptom observed in 209 patients 
(88.2%). Sputum production, fever, dyspnea, chest pain, anorexia, 
weight loss, hemoptysis, sleep disturbance and fatigue were 
observed in 80.6%, 46%, 37.6%, 13.1%, 9.7%, 8.9%, 7.6%, 5.1% and 
1.3% patients, respectively.  
Chronic obstructive pulmonary disease often coexists with other 
diseases and cardiovascular diseases are considered to be the 
major co-morbidity [1]. In the present study, co-morbid condition 
was found in 215 (90.7%) patients, with 48 patients (20.2%) 
suffering from a single co-morbid condition, and 167 (70.5%) 
suffering from more than one co-morbid condition. Majority of the 
patients (27%) were suffering from two co-morbid conditions. 
Hypertension (49.4%) was the most common co-morbid condition 
followed by respiratory failure (36.3%), diabetes mellitus (34.6%) 
and coronary artery disease (18.6%). However, in another study 
reported from Kerala, only 77.5% patients had a co-morbid 
condition with alcoholism being the most commonly observed co-
morbid condition; diabetes and hypertension were observed in 
30% patients’ each [9]. 
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Table 1: Age distribution among patients 
Age (Y) No. of patients (%) 
31-40 2 (0.8) 
41-50 7 (3.0) 
51-60 38 (16) 
61-70 94 (39.7) 
71-80 82 (34.6) 
81-90 14 (5.9) 
 
Among the respiratory infectious agents, bacteria and viruses have 
been implicated as a major risk factor for the development of a COPD 
exacerbation [7]. Hemophilus influenzae, Streptococcus pneumoniae 
and Moraxella catarrhalis are considered to be the most common 
pathogens involved in an exacerbation [10]. In the present study, 
sputum samples from 161 patients were sent for culture. Among 
these, for six patients, no organism grew in the culture while for 61 
patients the culture grew only normal flora. The most common 
microorganism isolated was Candida albicans (16%) followed by 
Pseudomonas aeruginosa (4.6%). Candida non-albicans and 
Escherichia coli each accounted for 3% of the cases. Aspergillus 
species were isolated from eight patients. Widespread use of inhaled 
steroids, systemic steroids, and antibiotics may be likely 
contributing to more frequent fungal colonization and growth [11]. 
Pseudomonas aeruginosa is beginning to be recognized as a relevant 
pathogen in COPD that is associated with an intense airway 
inflammation and poor prognosis for those with the disease. The 
prevalence of Pseudomonas aeruginosa infection in acute 
exacerbation is estimated to be approximately 4% [12], which is in 
concordance to our results. 
In the present study, majority of the patients were on multidrug 
therapy during both hospital stay (98.7%) and at the time of 
discharge (99.6%). This prescribing trend may be attributed to the 
goals of COPD therapy to minimize symptoms, to prevent recurrent 
exacerbations, to reduce the need for hospitalizations and to 
maintain near normal pulmonary function. 
During hospital stay, the most commonly prescribed drugs were 
ipratropium (91.6%) and levosalbutamol (88.2%). Nearly 76% 
patients were receiving the fixed dose combination (FDC) of 
levosalbutamol and ipratropium. Our findings are in concordance 
with Global Initiative for Obstructive Lung Disease (GOLD) 
guidelines, which recommends inhaled short acting beta-2 agonist 
(SABA) with or without short acting anticholinergic agent as the 
preferred bronchodilators for treatment of an exacerbation since 
they can rapidly improve respiratory symptoms during an 
exacerbation. Inhaled bronchodilators are known to reduce 
respiratory symptoms, increase exercise tolerance, reduce the 
frequency of exacerbations, and improve quality of life [1]. 
Combining bronchodilators with different mechanisms and duration 
of action may increase the degree of bronchodilation for equivalent 
or fewer side effects [13].  
Tiotropium was prescribed to 23.2% patients. Among the methyl 
xanthines, combination of etophylline+theophylline was most 
commonly prescribed (87.8%) followed by aminophylline (21.5%) 
and doxophylline (4.2%), which is similar when compared to 
another study from Kerala [9].  
As per GOLD guidelines, systemic corticosteroids and antibiotics can 
shorten recovery time, improve lung function and arterial hypoxemia, 
and reduce the risk of early relapse; treatment failure and length of 
hospital stay [1]. In the present study, during the hospital stay, 
systemic steroids like methylprednisolone, prednisolone and 
hydrocortisone were received by 64.5%, 29.9% and 29.1% patients, 
respectively. Inhaled corticosteroids like budesonide and fluticasone 
were used by 87.3% and 32.9% patients, respectively. It has been 
suggested that, hospitalized patients should receive intravenous 
treatment with anti pseudomonal penicillin, a third-generation 
cephalosporin, a newer macrolide or a fluoroquinolone, as determined 
by local bacterial resistance patterns [10]. In the present study, 
levofloxacin (47.7%) was the most commonly prescribed antibiotic, 
followed by cefoperazone+sulbactum (40.5%), ceftriaxone (35.4%), 
piperacillin+tazobactum (16.9%) and azithromycin (16.4%). In a 
previous study reported from Kerala, antibiotics were used in nearly 
87% patients with azithromycin being the most frequently used 
antibiotic followed by ampicillin, gentamicin, benzyl penicillin and 
cefotaxime [9]. Mucolytics were received by 27.8% patients, with 
ambroxol being most frequently prescribed (25.3%) followed by N-
acetylcysteine (2.5%). The drug utilization pattern during hospital 
stay is presented in table 2. 
 
Table 2: Drug category received during hospital stay 
Drug category No. of patients (%) 
Antibiotics 228 (96.2) 
Short acting beta-2 agonist 225 (94.9) 
Anticholinergic agent 223 (94.1) 
Inhaled corticosteroids 221 (93.2) 
Methylxanthines 217 (91.6) 
Systemic corticosteroids 197 (83.1) 
Long acting beta-2 agonist 87 (36.7) 
Mucolytics 66 (27.8) 
 
In the present study, at the time of discharge, the most commonly 
prescribed drugs were etophylline+theophylline (86.9%) followed 
by fluticasone (79.3%) and salmeterol (75.9%). Nearly 81% of 
patients received FDC of inhaled corticosteroid and long acting beta-
2 agonist (LABA), with 74% patients being prescribed 
fluticasone+salmeterol combination. Combination of inhaled 
corticosteroid and LABA has been reported to be more effective than 
the individual components in improving lung function and health 
status and reducing exacerbation in patients with moderate to very 
severe COPD [1]. Tiotropium and ipratropium were used by 56.5% 
and 19.4% patients, respectively. Other LABA prescribed were 
formoterol (17.7%) and indacaterol 2.1%. The utilization of LABA 
and tiotropium was thus more than doubled at the time of discharge. 
Systemic steroids like prednisolone, methylprednisolone and 
hydrocortisone were received by 73%, 7.2% and 1.7% patients, 
respectively. Mucolytics were received by 15.2% patients (ambroxol 
13.9%; N-acetylcysteine 0.8%; bromhexine 0.4%). The common 
antibiotics prescribed were cefpodoxime+potassium clavulanate 
(58.2%), levofloxacin (36.3%), doxycycline (10.5%), cefuroxime 
(7.2%) and clarithromycin (6.8%). The drug utilization pattern at 
the time of discharge is presented in table 3. 
 
Table 3: Drug category received at discharge 
Drug category No. of patients (%) 
Antibiotics 223 (94.1) 
Inhaled corticosteroids 222 (93.7) 
Methylxanthines 219 (92.4) 
Long acting beta-2 agonist 204 (86.1) 
Systemic corticosteroids 193 (81.4) 
Anticholinergic agents 171 (72.2) 
Short acting beta-2 agonist 70 (29.5) 
Mucolytics 36 (15.2) 
 
A limitation of the study was that data was collected retrospectively. 
However, the present study provides a representative data of drug 
utilization likely to be encountered in hospitalized COPD patients. 
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Consistent with the current guidelines, bronchodilators, 
corticosteroids and antibiotics were among the most commonly 
prescribed drugs for the management of an acute exacerbation in 
COPD patients. Characterization of the microbiological spectrum of 
COPD exacerbation may help in establishing an antimicrobial 
treatment protocol for better patient management. 
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